van de Ven Saskia, Kroep Judith R, Hamdy Neveen A T, Sleeboom Harm P, Nortier Hans W R
Leids Universitair Medisch Centrum, Leiden, Afd. Klinische Oncologie, The Netherlands.
Ned Tijdschr Geneeskd. 2010;154:A1951.
Pre-clinical and clinical studies increasingly suggest that the most potent nitrogen-containing bisphosphonates have antitumour effects. Bisphosphonates inhibit osteoclast-mediated bone resorption, and can thus delay the spread of skeletal metastases. Bisphosphonates might also inhibit tumour growth outside the skeleton by inducing apoptosis and inhibiting proliferation, adhesion, invasion, and angiogenesis of tumour cells. Recent trials suggest a possible synergistic antitumour effect between bisphosphonates and chemotherapy. A mechanism of action for bisphosphonates that could explain their possible antitumour effect and their synergy with chemotherapy is speculative and demands further investigation. The role of bisphosphonates in primary neoadjuvant treatment of breast cancer is promising, but must be further investigated.
临床前和临床研究越来越多地表明,最有效的含氮双膦酸盐具有抗肿瘤作用。双膦酸盐抑制破骨细胞介导的骨吸收,从而可以延缓骨转移的扩散。双膦酸盐还可能通过诱导肿瘤细胞凋亡并抑制其增殖、黏附、侵袭和血管生成来抑制骨骼外的肿瘤生长。最近的试验表明双膦酸盐与化疗之间可能存在协同抗肿瘤作用。双膦酸盐的作用机制,这可以解释其可能的抗肿瘤作用及其与化疗的协同作用,目前只是推测,需要进一步研究。双膦酸盐在乳腺癌新辅助治疗中的作用很有前景,但必须进一步研究。